Currently licenced direct oral anticoagulants selectively target thrombin (eg, dabigatran) or
coagulation factor Xa (eg, apixaban, betrixaban, edoxaban, and rivaroxaban). Designed to …

The most commonly prescribed oral anticoagulants worldwide are the vitamin K antagonists
(VKAs) such as warfarin. Factors affecting the pharmacokinetics of VKAs are important …

Background—Intracranial hemorrhage is the most feared complication of oral anticoagulant
treatment. The optimal treatment option for patients with atrial fibrillation who survive an …

The direct oral anticoagulants (DOACs) represent a major advance in oral anticoagulant
therapy and have replaced the vitamin K antagonists as the preferred treatment for many …

Objectives This cross-sectional survey explored the characteristics and outcomes of direct
oral anticoagulant (DOAC)–associated nontraumatic intracerebral hemorrhages (ICHs) by …

In the past six decades, heparin and warfarin were the primary anticoagulants prescribed for
treatment and prophylaxis of venous thromboembolism worldwide. This has been …

Introduction: This is a review of the drug interactions (DIs) between newer antidepressants
and oral anticoagulants (OACs): vitamin K antagonists (VKAs) and direct-acting OACs …

The novel oral anticoagulants or direct oral anticoagulants (DOAC) are becoming more
common in clinical practice for the prevention of stroke in non-valvular atrial fibrillation …

Stroke prevention with oral anticoagulation (OAC) is central to the modern management of
atrial fibrillation (AF) patients. 1 For many years, vitamin K antagonists (VKAs, eg warfarin) …

Background: Atrial Fibrillation (AF) is common in the elderly. A key component of AF
management is Oral Anticoagulant Therapy (OAT), consisting of Vitamin K Antagonists …